LEADOPTIK Information

FDA-cleared, LEADOPTIK's Last Inch Assessment (LIA) platform transforms the standard biopsy into a digital Tissue Intelligence™ workflow. By miniaturizing proprietary depth-imaging technology to the width of a human hair, we integrate high-resolution nano-optical probes directly into standard biopsy tools — enabling physicians to see, characterize, and confirm suspicious tissue in vivo and in real time. A compact reusable console paired with a single-use disposable probe provides depth-resolved imaging and real-time tissue differentiation at the needle tip, creating a seamless bridge between navigation and pathology. No switching devices. No workflow disruption. No blind guess. With the LIA platform now FDA-cleared and commercially deployed at Tier-1 hospitals.